Prime Medicine (PRME) PT Lowered to $7 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Price: $4.55 --0%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Stifel analyst Dae Gon Ha lowered the price target on Prime Medicine (NASDAQ: PRME) to $7.00 (from $8.00) while maintaining a Hold rating.
You May Also Be Interested In
- BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR100 at Piper Sandler
- Lending Tree (TREE) PT Lowered to $40 at JPMorgan
- Versant Media Group (VSNT) PT Lowered to $39 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
